Cardiovascular Revascularization Medicine
Volume 9, Issue 2 , Pages 66-70 , April 2008

The relationship between severity of coronary artery disease and plasma level of vascular endothelial growth factor

  • Yasar Kucukardali

      Affiliations

    • Department of Internal Medicine, Gulhane School of Medicine, Haydarpasha Training Hospital, Istanbul, Turkey
    • Corresponding Author InformationCorresponding Author. GATA Haydarpasa Egitim Hastanesi, Ic Hastaliklari Servisi, Istanbul, Turkey. Tel.: +90 216 542 32 13; fax: +90 216 348 78 80.
    • ,
  • Sebnem Aydogdu

      Affiliations

    • Department of Internal Medicine, Gulhane School of Medicine, Haydarpasha Training Hospital, Istanbul, Turkey
    • ,
  • Namik Ozmen

      Affiliations

    • Department of Cardiology, Gulhane School of Medicine, Haydarpasha Training Hospital, Istanbul, Turkey
    • ,
  • Arif Yonem

      Affiliations

    • Department of Endocrinology, Gulhane School of Medicine, Haydarpasha Training Hospital, Istanbul, Turkey
    • ,
  • Emrullah Solmazgul

      Affiliations

    • Department of Internal Medicine, Gulhane School of Medicine, Haydarpasha Training Hospital, Istanbul, Turkey
    • ,
  • Mustafa Ozyurt

      Affiliations

    • Department of Microbiology, Gulhane School of Medicine, Haydarpasha Training Hospital, Istanbul, Turkey
    • ,
  • Yilmaz Cingozbay

      Affiliations

    • Department of Cardiology, Gulhane School of Medicine, Haydarpasha Training Hospital, Istanbul, Turkey
    • ,
  • Aydogan Aydogdu

      Affiliations

    • Department of Internal Medicine, Gulhane School of Medicine, Haydarpasha Training Hospital, Istanbul, Turkey

Received 3 October 2007 ,Accepted 15 November 2007.

References 

  1. Maulik N. Reactive oxygen species drives myocardial angiogenesis?. Antioxid Redox Signal. 2006;8(11-12):2161–2168
  2. Pandya NM, Dhalla NS, Santani DD. Angiogenesis—a new target for future therapy. Vascul Pharmacol. 2006;44(5):265–274
  3. Jingjing L, Srinivasan B, Bian X, Downey HF, Roque RS. Vascular endothelial growth factor is increased following coronary artery occlusion in the dog heart. Mol Cell Biochem. 2000;214(1-2):23–30
  4. Alber HF, Frick M, Dulak J, et al. Vascular endothelial growth factor (VEGF) plasma concentrations in coronary artery disease. Heart. 2005;91(3):365–366
  5. Fleisch M, Billinger M, Eberli FR, Garachemani AR, Meier B, Seiler C. Physiologically assessed coronary collateral flow and intracoronary growth factor concentrations in patients with 1- to 3- vessel coronary artery disease. Circulation. 1999;100:1945–1950
  6. Blann AD, Belgore FM, McCollum CN, Silverman S, Lip PL, Lip GY. Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or type II diabetes. Clin Sci. 2002;102(2):187–194
  7. Losordo DW, Vale HR, Symes JF, et al. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation. 1998;98(25):2800–2804
  8. Celleti FL, Waugh JM, Amabile PG, Brendolan A, Hilfiker PR, Dake MD. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med. 2001;7(4):425–429
  9. Piek JJ, Koolen JJ, Hoedemaker G, David GK, Visser CA, Dunning AJ. Severity of single-vessel coronary arterial stenosis and duration of angina as determinants of recruitable collateral vessels during balloon angioplasty occlusion. Am J Cardiol. 1991;67(1):13–17
  10. Lin TH, Yen HW, Su HM, et al. Effects of total coronary artery occlusion on vascular endothelial growth factor and transforming growth factor beta. Kaohsiung J Med Sci. 2005;21(10):460–465
  11. Stewart DJ, Hilton JD, Arnold JM, et al. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment. Gene Ther. 2006;13(21):1503–1511
  12. Nakajima K, Tabata S, Yamashita T, et al. Plasma vascular endothelial growth factor level is elevated in patients with multivessel coronary artery disease. Clin Cardiol. 2004;27(5):281–286
  13. Gerrah R, Fogel M, Gilon D. Aspirin decreases vascular endothelial growth factor release during myocardial ischemia. Int J Cardiol. 2004;94(1):25–29
  14. Schultz A, Lavie L, Hochberg I, et al. Interindividual heterogeneity in the hypoxic regulation of VEGF: significance for the development of the coronary artery collateral circulation. Circulation. 1999;100(5):547–552
  15. Heeschen C, Dimmeler S, Hamm CW, Boersma E, Zeiher AM, Simoons ML. Prognostic significance of angiogenic growth factor serum levels in patients with acute coronary syndromes. Circulation. 2003;107(4):524–530
  16. Soeki T, Tamura Y, Shinohara H, Tanaka H, Bando K, Fukuda N. Serial changes in serum VEGF and HGF in patients with acute myocardial infarction. Cardiology. 2000;93(3):168–174
  17. Seko Y, Imai Y, Suzuki S, et al. Serum levels of vascular endothelial growth factor in patients with acute myocardial infarction undergoing reperfusion therapy. Clin Sci. 1997;92(5):453–454
  18. Ogawa H, Suefuji H, Soejima H, et al. Increased blood vascular endothelial growth factor levels in patients with acute myocardial infarction. Cardiology. 2000;93(1-2):93–99

PII: S1553-8389(07)00335-1

doi: 10.1016/j.carrev.2007.11.005

Cardiovascular Revascularization Medicine
Volume 9, Issue 2 , Pages 66-70 , April 2008

Article Tools